Lilly and Boehringer roll toward EU approval with diabetes combo

Eli Lilly ($LLY) and Boehringer Ingelheim secured a recommendation from European regulators for their combination diabetes treatment, making for a likely continental approval in the coming months. The drug is a fixed-dose combination of empagliflozin, an SGLT-2 inhibitor that forces excess blood sugars out through the urine, and metformin, a long-generic treatment designed to block glucose production in the liver. The pair plans to market the combination as Synjardy, expecting to pick up FDA approval later this year. Empagliflozin won approval last year and is marketed as Jardiance. More

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.